Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

To Evaluate the Effect of Food on the Pharmacokinetics (PK) of AZD0328

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: September 12, 2008
Last updated: October 28, 2008
Last verified: October 2008

September 12, 2008
October 28, 2008
September 2008
October 2008   (final data collection date for primary outcome measure)
PK variables [ Time Frame: Several PK samples during the study days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00752830 on Archive Site
Safety variables (adverse events, blood pressure, laboratory measurements and paper ECGs) [ Time Frame: During the whole treatment period ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
To Evaluate the Effect of Food on the Pharmacokinetics (PK) of AZD0328
A Phase I, Open, Randomized, Single-Dose, Two-Treatment (Fed Versus Fasting), Two-Period Cross-Over Single-Centre Study to Evaluate the Effect of Food on the Pharmacokinetics of AZD0328 Following Oral Administration (Capsule) in Healthy Male Subjects

The purpose of the study is to evaluate the effect of food on the pharmacokinetics of AZD0328 in healthy male volunteers. AZD0328 will be administered as a single oral dose (capsule) during two treatment periods, after food intake or during fasting condition.

Not Provided
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Drug: AZD0328
Oral capsule, single dose
  • Experimental: 1
    AZD0328 administration during fasting condition
    Intervention: Drug: AZD0328
  • Experimental: 2
    AZD0328 administration after food intake
    Intervention: Drug: AZD0328
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
October 2008
October 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male Caucasian subjects.
  • Clinically normal physical findings, laboratory values, vital signs and resting ECG as judged by the investigator.
  • Signed informed consent form

Exclusion Criteria:

  • History of clinically significant cardio or cerebrovascular, pulmonary, renal, hepatic, neurological, mental or gastrointestinal disorder (including dyspepsia or GERD) or any other major disorder that may interfere with the study.
  • Intake of another investigational drug or participation in another study which may interfere with the objectives of the study, within 12 weeks before the administration of the investigational product.
20 Years to 45 Years
Contact information is only displayed when the study is recruiting subjects
D0190C00009, EUdract NO 2008-003691-22
Didier Meulien, MD, Medical Science Director, Emerging AD & Cognition, AstraZeneca R&D, Södertälje, Sweden
Not Provided
Study Director: Didier Meulien, MD AstraZeneca R&D Södertälje, Sweden
Principal Investigator: Gabriella Samuelsson Palmgren, MD AstraZeneca Clinical Pharmacology Unit, AstraZeneca R&D Lund,Sweden
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP